ESC 365 - Predicted lifetime therapy benefit guided treatment effectively reduces residual cardiovascular risk in patients with symptomatic atherosclerotic disease

ESC Premium Access

Predicted lifetime therapy benefit guided treatment effectively reduces residual cardiovascular risk in patients with symptomatic atherosclerotic disease

Session: Young Investigator Award Session Population Sciences

Topic: Cardiovascular Risk Assessment

Speaker: Doctor S. Hageman (Utrecht, NL)

Event: ESC Congress 2020

Congress Presentation

Add to my library

About the speaker

Doctor Steven Hageman

University Medical Center Utrecht, Utrecht (Netherlands (The))

3 presentations

0 follower

3 more presentations in this session

Regular exercise after a diagnosis of atrial fibrillation and lower risks of cardiovascular disease: a nationwide population-based study

Speaker: Doctor H. Ahn (Seoul, KR)

Effect of beta blocker therapy following myocardial infarction in optimally treated patients in the reperfusion era - a Danish, nationwide, and registry-based cohort study

Speaker: Doctor A. Holt (Copenhagen, DK)

The association of artificial intelligence-enabled electrocardiogram-derived age (physiologic age) with atherosclerotic cardiovascular events in the community

Speaker: Doctor J. Medina-Inojosa (Rochester, US)

Access the full session

Young Investigator Award Session Population Sciences

Speakers: Doctor S. Hageman, Doctor H. Ahn, Doctor A. Holt, Doctor J. Medina-Inojosa

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources